Ralph Weichselbaum to Adenoviridae
This is a "connection" page, showing publications Ralph Weichselbaum has written about Adenoviridae.
Connection Strength
1.484
-
Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 2008 Mar; 15(3):133-9.
Score: 0.244
-
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res. 2007 Oct 15; 13(20):6217-23.
Score: 0.241
-
Gene therapy: the challenges of translating laboratory research into clinical practice. J Clin Oncol. 2003 Jun 15; 21(12):2230-1.
Score: 0.179
-
Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998 Mar; 5(3):293-300.
Score: 0.124
-
Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure. PLoS One. 2013; 8(8):e69025.
Score: 0.090
-
Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
Score: 0.071
-
ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):637-46.
Score: 0.056
-
Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 2006 Jan 01; 13(1):1-6.
Score: 0.053
-
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004 Sep 01; 10(17):5747-53.
Score: 0.049
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.049
-
TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther. 2002 Nov; 9(11):951-7.
Score: 0.043
-
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
Score: 0.042
-
Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int J Cancer. 2002 Feb 01; 97(4):410-5.
Score: 0.041
-
Radiation-inducible gene therapy. C R Acad Sci III. 1999 Feb-Mar; 322(2-3):225-8.
Score: 0.033
-
Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998 Nov-Dec; 5(6):344-9.
Score: 0.032
-
Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
Score: 0.030
-
Gene therapy of cancer. Lancet. 1997 May; 349 Suppl 2:SII10-2.
Score: 0.029
-
Increased injection number enhances adenoviral genetic radiotherapy. Radiat Oncol Investig. 1997; 5(5):220-6.
Score: 0.029
-
Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis. 2007; 24(7):521-31.
Score: 0.015
-
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15; 22(4):592-601.
Score: 0.012
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.011
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.010